Home/ Supplements/ Vitamin K/ Osteo-Guard

Osteo-Guard

product on market Tablet or Pill Douglas Laboratories Safety: 100/100
100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 50% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

Calcium, phosphorus, and vitamin K1 provide strong evidence for supporting bone mineral density and structural integrity. Boron may further assist in mineral metabolism, though research evidence for its efficacy is more limited. This combination focuses on essential nutrients required for skeletal maintenance.

AI-generated summary based on research evidence. Not medical advice.

Label

Product Label

Label for Osteo-Guard
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Tablet(s)
Serving Size
120
Servings
Other Combinations
Product Type
50%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

15 mcg (19% DV)
Within RDA (0.1× RDA) 275 studies (A:9, B:175)
Calcium
250 mg (25% DV)
120 mg (12% DV)
Within RDA (0.2× RDA) 13 studies (A:0, B:3)
0.5 mg
Market median: 3.0mg (58 products) 3 studies — no high-quality reviews

Other Ingredients

Cellulose Hydroxypropyl Methylcellulose Croscarmellose Sodium Vegetable Stearate Silica Water Polyethylene Glycol Magnesium Silicate (poly) ethenol Polysorbate 80
Claims

Label Claims — Verification

Unverified Nutrient
Unverified All Other
Info

Product Information

Directions for Use

Suggested Usage: As a dietary supplement, adults take 1 tablet daily with food or as directed by your healthcare professional.

Warnings & Precautions

WARNING: This product contains Vitamin K, which intereferes with the prescription drugs Coumadin and Warfarin. Do not take this if taking either of these drugs.

KEEP OUT OF REACH OF CHILDREN.

Tamper resistant package, do not use if outer seal is missing.

Formulation Notes

Osteo-Guard(R) provides calcium and phosphate from young bovine bone (as microcrystalline hydroxyapatite), trace minerals, bone matrix proteins, amino acids and glycosaminoglycans in their natural forms and physiologic ratios found in whole bone.

WARNING: This product contains Vitamin K, which intereferes with the prescription drugs Coumadin and Warfarin.

Additional Information

.For optimal storage conditions, store in a cool, dry place. (59(0) - 77(0)F/15(0) - 25(0)C) (35-65% relative humidity)

OSG

Metadata

Product Details

UPC / SKU7 45287 04011 9
DSLD Entry Date2014-03-25
Product TypeOther Combinations
FormTablet or Pill
DSLD ID31336
Data Updated2026-04-11
Research

Research Evidence

332
Research Sources
59
Avg Quality
220
Meta Analysis
56
Systematic Review
30
Rct
16
Clinical Trial
3
Guideline
3
Regulatory Source
1
Narrative Review
1
Other
1
Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017 PubMed DOI
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016 PubMed DOI
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018 PubMed DOI
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022 PubMed DOI
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012 PubMed DOI
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013 PubMed DOI
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
View all evidence for Vitamin K →
Compare

Similar Products

View all Vitamin K products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.